Regeneron is a biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.
Marketed Products
Regeneron has received marketing approval from the U.S. Food and Drug Administration (FDA) and from the European Medicine's Agency for ARCALYST® (rilonacept) Injection for Subcutaneous Use for a rare inflammatory condition.
Product Candidates
In clinical trials for the prevention of gout flares in patients initiating urate-lowering therapy and in the treatment of acute gout flares.
In clinical trials for Wet Age-related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO), and Diabetic Macular Edema (DME).
In clinical trials for a wide range of solid tumors.
Five human antibodies from the sanofi-aventis collaboration are in clinical development today, with the goal of advancing an average of four to five new antibodies into clinical development each year.
